(Hypertension. 2001;37:58.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.
Correspondence to Patrick J. Pagano, PhD, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202. E-mail ppagano1{at}hfhs.org
AbstractIntercellular adhesion
molecule-1 (ICAM-1), part of an immunoglobulin-like superfamily of
adhesion molecules, is involved in several
cardiovascular diseases. We investigated whether in
vivo angiotensin II (Ang II) increases ICAM-1 in rats.
Sprague-Dawley rats were infused with vehicle or Ang II (750 µg
· kg-1 · d-1 SC) for 7 days. The
contribution of Ang II receptors to ICAM-1 expression was investigated
with a nonpeptide Ang II type 1 (AT1) receptor
antagonist losartan (30 mg · kg-1
· d-1 in drinking water). Systolic blood
pressure was elevated in Ang IItreated animals compared with
sham-treated controls, and losartan blocked this increase.
Tumor necrosis factor (TNF)-
(5 µg/kg IP bolus), a prototype
inducer of ICAM-1, was administered as a positive control for ICAM-1
expression. After treatment, hearts were frozen in liquid nitrogen;
homogenates were subjected to SDS-PAGE and
immunoblotted with an anti-rat ICAM-1 monoclonal antibody.
We detected a predominantly high-molecular-weight band in
homogenates from nonTNF-
treated rats, which was
enhanced by 80±5% in TNF-
treated rats. This band measured
200
kDa, which is the molecular weight of ICAM-1 in its native dimer form.
The same band was detected in homogenates from sham and Ang
IItreated rats, with the latter showing a 150±10% increase in
ICAM-1 versus sham controls. Immunoprecipitation of rat heart
homogenates with anti-rat ICAM-1 antibody resulted in a
dominant band of the same molecular weight as samples not treated with
antibody. Losartan prevented enhanced expression of ICAM-1 in
the presence of Ang II but had no effect on basal ICAM-1 expression.
Phenylephrine, an
-agonist (3 mg ·
kg-1 · d-1 ), was infused for 1 week
but had no effect on ICAM-1 expression, even though systolic
blood pressure was elevated to the same level as in rats treated with
Ang II. Thus, heart ICAM-1 expression is enhanced via AT1
receptor activation independent of hypertension. Ang IIinduced ICAM-1
expression was time and dose dependent, with maximal expression
occurring within 5 to 7 days at 100 to 750 µg/kg Ang II.
Immunohistochemical staining demonstrated markedly increased ICAM-1
levels in the perivascular area in Ang IIinfused rats.
Monocyte/macrophage accumulation was significantly greater in
Ang IItreated rat hearts than in sham-treated hearts (10±1;
P<0.001; n=5). Thus during inflammation, overexpression
of ICAM-1 may contribute to cardiovascular damage in
diseases characterized by increased activity of the
renin-angiotensin system.
Key Words: angiotensin II cell adhesion molecules hypertension, experimental losartan phenylephrine
This article has been cited by other articles:
![]() |
G. B. Silva and J. L. Garvin Angiotensin II-Dependent Hypertension Increases Na Transport-Related Oxygen Consumption by the Thick Ascending Limb Hypertension, December 1, 2008; 52(6): 1091 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ando, J. Zhou, M. Macova, H. Imboden, and J. M. Saavedra Angiotensin II AT1 Receptor Blockade Reverses Pathological Hypertrophy and Inflammation in Brain Microvessels of Spontaneously Hypertensive Rats Stroke, July 1, 2004; 35(7): 1726 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, F. Yang, X.-P. Yang, M. Jankowski, and P. J. Pagano NAD(P)H Oxidase Mediates Angiotensin II-Induced Vascular Macrophage Infiltration and Medial Hypertrophy Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 776 - 782. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |